(NASDAQ: NAGE) Niagen Bioscience's forecast annual revenue growth rate of 15.8% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 283.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.14%.
Niagen Bioscience's revenue in 2025 is $116,303,000.On average, 7 Wall Street analysts forecast NAGE's revenue for 2025 to be $10,287,333,923, with the lowest NAGE revenue forecast at $9,816,791,477, and the highest NAGE revenue forecast at $10,685,301,179. On average, 6 Wall Street analysts forecast NAGE's revenue for 2026 to be $12,401,584,814, with the lowest NAGE revenue forecast at $11,611,233,010, and the highest NAGE revenue forecast at $13,231,015,566.
In 2027, NAGE is forecast to generate $14,630,679,962 in revenue, with the lowest revenue forecast at $13,857,873,808 and the highest revenue forecast at $15,274,286,325.